CASE FOR DIAGNOSIS

Widespread Nodules in an Immunosuppressed Adult

Nódulos diseminados en un adulto inmunosuprimido

Medical History

A 72-year-old man was admitted to hospital with a chronic subdural hematoma; he had been on treatment with dexamethasone 12 mg a day for the previous 3 months to prevent cerebral edema. During his stay, widespread subcutaneous nodules that had been present for 3 weeks were detected, associated with low-grade fever.

Physical Examination

The patient had multiple subcutaneous nodules in different areas of the body, but mostly affecting the trunk. They were hard to palpation and not fixed to the deep layers. Several of the nodules showed signs of inflammation (Fig. 1).

Histopathology

One of the nodules was biopsied to obtain material for histology and the purulent material was drained. Hematoxylin-eosin staining revealed a dense inflammatory infiltrate in the deep dermis and the presence of septate hyphae with 45° branching (Fig. 2).

Additional Tests

Laboratory tests showed leukocytosis with neutrophilia and the chest radiograph showed a cavitated lesion in the left parahilar region (Fig. 3). Chest computed tomography showed a well-circumscribed tumor measuring 5 cm in diameter in the anterior segment of the left upper lobe, of heterogeneous density and with an air-fluid level. Fine-needle aspiration was performed but insufficient material was obtained for diagnosis. Blood cultures were negative.

What Is Your Diagnosis?

Please cite this article as: Masferrer E, Vidal D. Nódulos diseminados en un adulto inmunosuprimido. Actas Dermo-Sifiliogr. 2011;102:543-44.
Diagnosis
Secondary cutaneous aspergillosis.

Additional Tests
Culture of the skin biopsy specimen and sputum were positive for *Aspergillus fumigatus*.

Clinical Course and Treatment
Despite intravenous treatment with caspofungin 50 mg/24 h and voriconazole 200 mg/12 h, the patient died on day 13 of admission.

Comment
Aspergillosis is an infection caused by *Aspergillus* species, the most common of which are *Aspergillus flavus* and *A. fumigatus*. The infection tends to affect immunosuppressed patients as the main risk factors are neutropenia, corticosteroid therapy, and solid and hematological malignancies. Aspergillosis has also been associated with construction work or earth movements at or near hospitals due to the higher concentration of fungal spores in the environment.

Cutaneous aspergillosis has 3 clinical variants. The primary variant appears following direct inoculation of the fungus into the skin.1 The secondary, or hematogenous, variant occurs when the fungus travels from the lung to the skin via the bloodstream.2 Secondary aspergillosis accounts for just 4% of all cases of systemic aspergillosis.3 The third variant is the result of direct invasion by the fungus of the skin from an adjacent focus of infection, such as sinus infection. *A. flavus* and *A. fumigatus* are the most common causes of primary and secondary aspergillosis, respectively. Other, less common, causal agents are *Aspergillus niger*, *Aspergillus terreus*, and *Aspergillus nidulans*.

The diagnosis of cutaneous aspergillosis requires skin biopsy. Staining with periodic acid Schiff and methenamine silver reveals septate hyphae with uniform 45° branching. Cultures are useful for confirming diagnosis and identifying the species responsible for the infection. Blood cultures are negative in most cases. Histology together with chest radiographs and CT scans are essential for the diagnosis of primary lung infection. A sputum culture, however, is not very useful as it does not distinguish between lung colonization and invasive disease.

Treatments include intravenous voriconazole, posaconazole, amphotericin B, and caspofungin.4 Despite treatment, secondary cutaneous aspergillosis has an associated mortality of over 90%.5

Conflicts of Interest
The authors declare that they have no conflicts of interest.

References

E. Masferrer,* D. Vidal
Servicio de Dermatología, Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despí, Barcelona, Spain

*Corresponding author.
E-mail address: emilimasferreriniubo@gmail.com

(E. Masferrer).